The series has been a United States playbook, the programs, the agencies, the proposal, the money, and the strategy all read from American law and American solicitations. This article steps outside the United States to survey the analogs other advanced economies have built, because the problem the programs solve is not peculiarly American and the instruments other countries use to solve it illuminate the American ones by contrast. One idea organizes the survey, that every advanced economy faces the same market failure, the private underfunding of early-stage high-risk technology that the valley-of-death article described, and each has built some public instrument to fund the risk reduction that private capital will not, so the analogs are not copies of a single design but different answers to one shared question. The answers differ along a few structural axes, the instrument used, a procurement contract or a grant or a tax credit or an equity stake, whether the money is non-dilutive or dilutive, whether it is competed against a stated challenge or open to any idea, and whether it is staged in phases or paid in one shot, and the survey is organized around those axes rather than around a tour of every country. The usual caution applies with unusual force here, that foreign programs change their names and their structures often, the British and the Dutch programs both having been renamed recently, so the specifics below are current-as-of and each country’s own program authority is the only reliable source.

The Common Problem

The reason every advanced economy intervenes is the same one the American program rests on. Early-stage high-risk technology is a market failure, since the firm that develops it cannot capture all the value it creates and the private investor cannot price a risk that has not yet been reduced, so the work that would benefit the economy goes unfunded by the market that should fund it. A government that wants the technology anyway, for its economy or its defense or its public services, must therefore supply the capital the market withholds, and the choice of how to supply it is a choice of industrial policy that each country makes differently. The American answer, the staged competitive award that the introductory article laid out, is one design among several, and seeing it beside the others shows which of its features are essential to the problem and which are particular to the United States.

The Procurement Copies

The closest analogs are the programs built deliberately on the American model, the challenge-driven staged procurement of research from small firms. The United Kingdom ran its Small Business Research Initiative on exactly this pattern for years and renamed it Contracts for Innovation in 2024, a scheme in which Innovate UK and a public body pose a specific challenge and award fully funded research contracts in phases, the firm keeping its intellectual property, which is the American staircase under a British name. The Netherlands ran a program named SBIR outright, a three-phase competition of feasibility then development then a market launch in which the government is the first customer, recently rebranded the Innovation Impact Challenge but structurally the same. Australia built its Business Research and Innovation Initiative explicitly on the American program and on its own states’ versions, a feasibility grant followed by a larger proof-of-concept grant against challenges its agencies nominate, and Canada runs Innovative Solutions Canada, whose challenge stream awards a feasibility phase and then a prototype phase to small Canadian firms in a structure that closely mirrors the two American phases. Japan reformed its own long-standing SBIR in 2021 to coordinate it across ministries under the Cabinet Office and to focus it on research-intensive startups, splitting its work into a procurement-needs type and a social-issues type and implementing it through agencies including the New Energy and Industrial Technology Development Organization, so the phased model has been adopted across several continents. What unites these is the recognizable American shape, a competed challenge, a staged award, a small-firm recipient, and the government positioned as an eventual customer.

The European Grant Programs

The largest non-American instruments are European and they are mostly grants rather than procurement. The European Union funds research and innovation through its Horizon Europe framework, the umbrella under which most Union science money flows, and within it the European Innovation Council runs the instrument closest to the American program for small firms, the Accelerator, which funds high-risk high-impact innovation by single companies. Alongside the Union’s own programs the intergovernmental Eureka network, through schemes such as Eurostars, coordinates national funding so that firms in different countries can collaborate on a single funded project, a cross-border dimension the American program does not have. National grant programs sit beneath the Union ones, Germany running its Central Innovation Programme for the Mittelstand, the standing federal grant for its small and mid-sized firms that reimburses part of their research costs and funds cooperation projects pairing firms with research institutions, the collaboration the next section takes up. The European model differs from the American one in that the grant, rather than the procurement contract, is the usual instrument, so the European government funds the work without positioning itself as the customer for the result, which changes the transition path the firm must find.

The Research-Collaboration Analog

The series pairs SBIR with STTR, and the two differ in one feature, that the eligibility rules require an STTR award to be carried out in partnership with a research institution under a minimum division of the work, so the international question is not only whether the single-firm model has analogs but whether the company-and-institution model does. It does, and abroad that collaborative model is often the default rather than a separate track, since the European framework funds many of its projects as consortia that must join partners across organizations and the Eureka and Eurostars schemes are built around collaboration between firms and research performers in more than one country. Germany’s cooperation projects fund the same firm-and-institution pairing, and South Korea has recently moved to add a program of the STTR kind alongside its existing schemes, so the research-partnering idea the STTR embodies is widespread and in several places the ordinary way of funding rather than a distinct program. The American separation of a single-firm SBIR from a partnered STTR is therefore itself a design choice, since other countries fold the partnership into the main instrument rather than running it as a parallel one.

The Tax-Credit Instrument

A wholly different instrument funds research through the tax system rather than through an award. Canada operates the Scientific Research and Experimental Development program, a tax credit that reimburses a portion of a firm’s qualifying research spending, and many countries run broadly similar research-relief schemes. The contrast with the American award is sharp, since a tax credit is an entitlement that any qualifying firm receives for work it chose and funded itself rather than a competed award for work the government wants done, so it is non-dilutive and broad-based but it neither directs the research toward a public need nor supplies the capital before the work rather than after it. A firm that can fund its own research and wants no direction prefers the credit, while a firm that needs the capital up front and is willing to address a stated need prefers the award, so the two instruments serve different firms and the United States and Canada both in fact run versions of each.

The State as Investor

At the dilutive end of the spectrum the government takes a stake rather than giving a grant. Israel built much of its technology economy on public innovation funding through the body now called the Israel Innovation Authority, whose grants have historically carried royalty obligations that repay the state from the resulting revenue, a structure partway between a grant and an investment. The European Accelerator has moved the same direction with its blended finance, combining a non-dilutive grant with a direct equity investment through a public fund, so that the Union takes an ownership position in the companies it backs rather than only funding their work. South Korea runs a matching model of its own, its Tech Incubator Program for Startups, in which the government matches the capital a private operator invests in a startup so that public and private money enter together. This model treats the public money as patient capital that shares in the upside, the opposite pole from the American program, which the money article described as deliberately non-dilutive, taking no equity and leaving the firm whole, and the choice between them is a choice about whether the public should profit from the technologies it funds.

Defense and Dual-Use

Defense ministries fund innovation through their own analogs, and the newest of note is multinational. The North Atlantic Treaty Organization established the Defence Innovation Accelerator for the North Atlantic to develop emerging and dual-use technologies across its member states, running accelerator sites and test centers and awarding funding to startups whose technologies serve both commercial and defense ends. It is an alliance-level analog rather than a national one, and its dual-use focus echoes the commercial-and-government posture the strategy article recommended, so the defense end of the international landscape is converging on the same dual-use logic the American defense agencies follow.

The Axes of Difference

Laid side by side the analogs map onto a small set of design choices. The table below places the representative programs against those four choices, the instrument used, whether the money is dilutive, whether selection is challenge-driven or open, and whether the award is staged in phases or paid in one shot.

Program Instrument Dilutive Selection Staging
United States SBIR and STTR Procurement or grant No Challenge Phased
United Kingdom Contracts for Innovation Procurement No Challenge Phased
Netherlands Innovation Impact Challenge Procurement No Challenge Phased
Australia Business Research and Innovation Initiative Grant No Challenge Phased
Canada Innovative Solutions Canada Grant No Challenge Phased
Japan SBIR Procurement or grant No Challenge Phased
European Union EIC Accelerator Grant plus equity Partly Open Single-shot
European Union Horizon and Eureka Grant No Open Varies
Germany Central Innovation Programme Grant No Open Single-shot
Canada Scientific Research and Experimental Development Tax credit No Open None
Israel Innovation Authority Royalty-bearing grant Royalty Open Varies
South Korea Tech Incubator Program Matched investment Partly Open Phased
NATO DIANA Grant and accelerator No Challenge Phased

These choices are not mutually exclusive, since most countries run more than one instrument, the United States and Canada each operating both a competed award and a broader mechanism. Against these axes the American program is a non-dilutive, challenge-driven, phased procurement, a combination that several countries copied precisely because that combination directs public money at public needs while leaving the firm its ownership, and the portfolio strategy the previous article described applies to any of these instruments since a firm operating internationally can stack a European grant, a national procurement award, and a tax credit much as an American firm stacks its federal award and its state match.

Scale and the UAV Case

The running example would find a path under most of these regimes. The small company building its unmanned aircraft could pursue a British or Dutch or Australian or Canadian challenge contract on a staircase much like the American one, apply to the European Accelerator for a grant and a blended equity investment, claim a research tax credit on the work it self-funds, or seek a royalty-bearing grant of the Israeli kind, and as a dual-use airframe it could compete for the alliance-level defense funding as readily as for a national program. The catch is that these programs fund national firms, so reaching most of them in practice would require the company to establish a local entity rather than to apply from abroad, and what travels freely is the model rather than any single company’s eligibility. The strategic logic would not change, since the company would still use whichever non-dilutive capital it could reach to reduce its technical risk before raising the dilutive private capital that scales it, and it would still choose the instruments that advance its destination rather than the ones that merely happen to be open. The vocabulary and the agencies would differ, but the staircase from feasibility to prototype to market, staged against demonstrated risk reduction, is recognizably the same climb in every country.

Out of Scope

Several matters belong elsewhere or to specialists. The detailed eligibility rules, the application mechanics, and the funding figures of each foreign program are matters for that program’s own authority rather than for this survey, and they change frequently enough that any figure quoted here would soon mislead. A full accounting of every national program is beyond one article, so this survey covers the instruments and the representative examples rather than an exhaustive list, and it omits the programs of countries it does not name not because they lack analogs but because the axes are better shown by a few clear cases than by many. Nothing here is legal, financial, or tax advice for pursuing any particular foreign program, and the worked capstone that follows returns to the United States.

Conclusion

Every advanced economy faces the same market failure in early-stage high-risk technology, and each funds the risk reduction the market will not, so the American program is one answer among many to a shared question rather than a unique invention. The answers differ in their instrument, a procurement contract or a grant or a tax credit or an equity stake, in whether the money is non-dilutive or dilutive, challenge-driven or open, and phased or single-shot, and the American combination of a non-dilutive challenge-driven staged procurement was deliberate enough that the United Kingdom, the Netherlands, Australia, Canada, and Japan all built programs on its pattern. Seeing the analogs beside the American program shows that the staircase from feasibility to prototype to market is the durable idea and the rest is national detail, which is the frame the concluding capstone will apply to one company climbing that staircase in full.

References